Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAFV600E Melanoma

J Wang, J Chen, DD Miller, W Li - Molecular cancer therapeutics, 2014 - AACR
Acquired clinical resistance to vemurafenib, a selective BRAFV600E inhibitor, arises
frequently after short-term chemotherapy. Because inhibitions of targets in the RAF–MEK …
被引用次数：43 相关文章
[HTML] nih.gov

[HTML][HTML] Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcome Vemurafenib Acquired Resistance in BRAFV600E Melanoma

J Wang, J Chen, DD Miller, W Li - Molecular cancer therapeutics, 2014 - ncbi.nlm.nih.gov
Acquired clinical resistance to vemurafenib, a selective BRAF V600E inhibitor, arises
frequently after short term chemotherapy. Since inhibitions of targets in the RAF-MEK-ERK …

Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma

J Wang, J Chen, DD Miller, W Li - Molecular cancer …, 2014 - pubmed.ncbi.nlm.nih.gov
Acquired clinical resistance to vemurafenib, a selective BRAF (V600E) inhibitor, arises
frequently after short-term chemotherapy. Because inhibitions of targets in the RAF-MEK …

Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma.

J Wang, J Chen, DD Miller, W Li - Molecular Cancer Therapeutics, 2013 - europepmc.org
Acquired clinical resistance to vemurafenib, a selective BRAF V600E inhibitor, arises
frequently after short term chemotherapy. Since inhibitions of targets in the RAF-MEK-ERK …

Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcome Vemurafenib Acquired Resistance in BRAFV600E Melanoma

J Wang, J Chen, DD Miller, W Li - 2013 - researchgate.net
Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcome
Vemurafenib Acquired Resistance in BRAFV600E Page 1 12/16/13 Synergistic …

Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma.

J Wang, J Chen, DD Miller, W Li - Molecular Cancer Therapeutics, 2013 - europepmc.org
Acquired clinical resistance to vemurafenib, a selective BRAF V600E inhibitor, arises
frequently after short term chemotherapy. Since inhibitions of targets in the RAF-MEK-ERK …

[引用][C] Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcome Vemurafenib Acquired Resistance in BRAFV600E Melanoma

JIN WANG, J CHEN… - Molecular …, 2014 - American Association for Cancer …